Topic: neurological disorders
The week’s biotech developments included a brain-penetrating compound from scorpion venom and a pact to develop virus-based cancer drugs.
Two years after its founding, Biomatics Capital Partners has raised $300 million for its second fund and signed on two new venture partners.
Discovery made by Virginia Tech scientists on perineuronal nets could open up new approach for acquired epilepsy.
Fierce 15 winner Jnana Therapeutics has installed co-founder Joanne Kotz, Ph.D., as its new CEO. She has served as president since December 2017.
The startup, founded just last year and a JLABS alumnus, is working on next-gen tech.
Researchers accidentally reprogrammed mature neurons into dopamine-producing neurons—a discovery that could spark new therapies for brain diseases.
Coda Biotherapeutics' goal is to create a gene therapy that can be switched on and off, and dialed up and down.
Scrutinizing a newly discovered neuron could help guide efforts to find treatments for neurological diseases.
The brain's lymphatic vessels might play a critical role in Alzheimer's and could be a new target for treatment.